Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

NCT07037680 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Non-Small Cell Lung Cancer
Thoracic Radiotherapy
Safety

Interventions

DRUG: Anlotinib

Sponsor

JIANYANG WANG